PUBLISHER: Mordor Intelligence | PRODUCT CODE: 391390
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 391390
The increasing burden of bladder cancer is the major factor driving the market in the European region. According to the estimates of Globocan, bladder cancer ranks fifth among the most frequently diagnosed cancer types, with about 197,105 new cases predicted in 2018 for both sexes, representing around 5% of the total cases. Moreover, increasing awareness about bladder cancer and related therapies is fueling the growth of the European bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing awareness about bladder diseases and available therapies and innovations in novel drug development, are also contributing to the growth of the market studied. However, various factors, such as rise in the number of patent expiration is estimated to impede the growth of the studied market.
Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.
The market studied is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., Sanofi SA, etc. hold a substantial market share in the European bladder cancer therapeutics and diagnostics market.